Novel agents that downregulate EGFR, HER2, and HER3 in parallel

EGFR, HER2, and HER3 contribute to the initiation and progression of human cancers, and are therapeutic targets for monoclonal antibodies and tyrosine kinase inhibitors. An important source of resistance to these agents arises from functional redundancy among EGFR, HER2, and HER3. EGFR family member...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Renan Barroso, Law, Mary Elizabeth, Jahn, Stephan Christopher, Davis, Bradley John, Heldermon, Coy Don, Reinhard, Mary, Castellano, Ronald Keith, Law, Brian Keith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496366/
https://www.ncbi.nlm.nih.gov/pubmed/25865227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496366/
https://www.ncbi.nlm.nih.gov/pubmed/25865227

Ejemplares similares